Qurient Co. Ltd (115180) - Total Liabilities

Latest as of March 2026: ₩21.88 Billion KRW ≈ $14.83 Million USD

Based on the latest financial reports, Qurient Co. Ltd (115180) has total liabilities worth ₩21.88 Billion KRW (≈ $14.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Qurient Co. Ltd annual equity growth to track the company's year-over-year net asset growth rate.

Qurient Co. Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Qurient Co. Ltd's total liabilities have evolved over time, based on quarterly financial data.

Qurient Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Qurient Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Hankook Shell Oil
KO:002960
Korea ₩59.90 Billion
Ovzon AB
ST:OVZON
Sweden Skr668.00 Million
Universal Logistics Holdings Inc
NASDAQ:ULH
USA $1.24 Billion
Anhui Zhongyuan New Materials Co Ltd
SHG:603527
China CN¥3.04 Billion
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
China CN¥987.73 Million
Genesco Inc
NYSE:GCO
USA $831.59 Million
Medistim ASA
OL:MEDI
Norway Nkr151.23 Million
Prince Housing & Development Corp
TW:2511
Taiwan NT$21.20 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Qurient Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 115180 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 19.26 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.40 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qurient Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qurient Co. Ltd (2014–2025)

The table below shows the annual total liabilities of Qurient Co. Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩22.80 Billion
≈ $15.45 Million
+185.93%
2024-12-31 ₩7.97 Billion
≈ $5.40 Million
+35.53%
2023-12-31 ₩5.88 Billion
≈ $3.99 Million
+79.65%
2022-12-31 ₩3.28 Billion
≈ $2.22 Million
-7.61%
2021-12-31 ₩3.55 Billion
≈ $2.40 Million
-16.46%
2020-12-31 ₩4.24 Billion
≈ $2.88 Million
+35.36%
2019-12-31 ₩3.14 Billion
≈ $2.12 Million
-17.30%
2018-12-31 ₩3.79 Billion
≈ $2.57 Million
+230.89%
2017-12-31 ₩1.15 Billion
≈ $776.40K
-39.40%
2016-12-31 ₩1.89 Billion
≈ $1.28 Million
+96.17%
2015-12-31 ₩963.76 Million
≈ $653.12K
-97.09%
2014-12-31 ₩33.11 Billion
≈ $22.44 Million
--

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$434.60 Million
₩641.30 Billion KRW
Market Cap Rank
#12827 Global
#343 in Korea
Share Price
₩17210.00
Change (1 day)
+3.30%
52-Week Range
₩10000.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more